These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
615 related items for PubMed ID: 10189388
1. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients. Vázquez L, Encinas MP, Morín LS, Vilches P, Gutiérrez N, García-Sanz R, Caballero D, Hurlé AD. Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388 [Abstract] [Full Text] [Related]
2. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections. Portolés A, Palau E, Puerro M, Vargas E, Picazo JJ. Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294 [Abstract] [Full Text] [Related]
3. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study]. Codina C, Miró JM, Tuset M, Claramonte J, Gomar C, Gotsens R, Gómez B, Suárez S, Abellana R, Ascaso C, Cartaña R, Rodríguez E, Asenjo M, Carné X, Trilla A, Marco F, Gómez J, Brunet M, Pomar JL, Gatell JM, Ribas J. Med Clin (Barc); 2000 Mar; 114 Suppl 3():54-61. PubMed ID: 10994565 [Abstract] [Full Text] [Related]
5. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Aksoylar S, Cetingül N, Kantar M, Karapinar D, Kavakli K, Kansoy S. Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510 [Abstract] [Full Text] [Related]
6. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes]. Figuera A, Tomás JF, Hernández L, Jiménez ML, Peñarrubia MJ, del Rey MC, Arranz R, Cámara R, López-Lorenzo JL, Fernández-Rañada JM. Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537 [Abstract] [Full Text] [Related]
7. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation. D'Antonio D, Staniscia T, Piccolomini R, Fioritoni G, Rotolo S, Parruti G, Di Bonaventura G, Manna A, Savini V, Fiorilli MP, Di Giovanni P, Francione A, Schioppa F, Romano F. Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082 [Abstract] [Full Text] [Related]
9. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Zengin E, Sarper N, Kılıç SC. Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156 [Abstract] [Full Text] [Related]
10. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients. Metallidis S, Kollaras P, Giannakakis T, Seitanidis B, Kordosis T, Nikolaidis J, Hatzitolios A, Nikolaidis P. Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729 [Abstract] [Full Text] [Related]
11. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Harter C, Schulze B, Goldschmidt H, Benner A, Geiss HK, Hoppe-Tichy T, Ho AD, Egerer G. Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334 [Abstract] [Full Text] [Related]
15. [Value of the combination of piperacillin and pefloxacin possibly followed by vancomycin in the treatment of febrile neutropenia in nephrotoxic chemotherapy]. Kattan J, Droz JP, Culine S, Ribrag V, Boutan-Laroze A, Andremont A. Bull Cancer; 1992 Feb; 79(7):705-12. PubMed ID: 1467596 [Abstract] [Full Text] [Related]
17. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II. Kusowska J. Acta Pol Pharm; 2005 Feb; 62(6):491-5. PubMed ID: 16583990 [Abstract] [Full Text] [Related]
18. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I. Kusowska J. Acta Pol Pharm; 2005 Feb; 62(6):485-90. PubMed ID: 16583989 [Abstract] [Full Text] [Related]